$3M In Federal Grants Awarded: Big Win For The Support Of CBD Research

$3m in Federal Grants Awarded: Big win for the support of cbd Research

$3M in Federal grants awarded to study CBD, minor cannabinoids, and terpenes for pain-relieving properties.

On September 19 2019, The Federal Government awarded $3M across nine grants to support the study of cannabinoids including CBD (but excluding THC).  The studies funded include a grant to the Children’s Hospital of Boston to study CBD-mediated analgesic effects, and a grant to University of California, San Francisco, to study the effects of minor cannabinoids on inflammatory and neuropathic pain.  The grants are funded by the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH).  

What is the goal of the studies?

The studies will focus on the mechanisms of action and potential optimization of CBD and other minor cannabinoids as well as terpenes found in the cannabis plant. The goal is to “strengthen the evidence regarding cannabis components and whether they have potential roles in pain management” according to the NIH press release.

The press release makes a point of noting the limited potential use cases for THC’s demonstrated pain relieving abilities due to its “psychoactive effects and abuse potential”.  There are more than 110 cannabinoids and 120 terpenes found in the cannabis plant, the release notes, but THC is the only cannabinoid that has been studied extensively to date.

Lab tested CBD Oil

What does this mean for CBD users?

This is yet another step towards a deeper understanding of how we can treat persistent symptoms of pain through non-traditional remedies rather than chemical or pharmaceutical approaches.  “The treatment of chronic pain has relied heavily on opioids, despite their potential for addiction and overdose and the fact that they often don’t work well when used on a long-term basis,” said Helene Langevin, M.D., director of NCCIH. “There’s an urgent need for more effective and safer options.”

Want to learn more?  Scroll for a list of all of the grants.

Here is a full summary of the grants awarded to study minor cannabinoids and terpenes for potential pain-relieving properties:

  • Mechanism and Optimization of CBD-Mediated Analgesic Effects; Boston Children’s Hospital, Boston; Zhigang He, Ph.D., B.M., and Kuan Hong Wang, Ph.D. This project will investigate how the pain-relieving effects of cannabidiol (CBD) and other minor cannabinoids may be modulated by the activity of potassium-chloride cotransporter 2 (KCC2), a chloride extruder expressed in most neurons. (Grant 1R01AT010779)
  • Neuroimmune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Pain; University of California, San Francisco; Judith Hellman, M.D., and Mark A. Schumacher, M.D., Ph.D. This project will explore the effects of minor cannabinoids on inflammatory and neuropathic pain in vitro and in vivo, focusing on the interactions of the cannabinoids with the peripheral receptor called TRPV1 and a cannabinoid receptor, CB1R. (Grant 1R01AT010757)
  • Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics; Research Triangle Institute, Research Triangle Park, North Carolina; Jenny L. Wiley, Ph.D. This project will evaluate purified biosynthesized minor cannabinoids and selected terpenes alone and in planned combinations to determine their potential efficacy as pain relievers against acute thermal, inflammatory, neuropathic, and visceral pain. (Grant 1R01AT010773)
  • Identifying the Mechanisms of Action for CBD on Chronic Arthritis Pain; New York University School of Medicine, New York City; Yu-Shin Ding, Ph.D. This project will use neuroimaging studies and behavioral assessments to investigate the mechanisms of action of CBD in the modulation of chronic pain associated with osteoarthritis in a mouse model. (Grant 1R21AT010771)
  • Synthetic Biology for the Chemogenetic Manipulation of Pain Pathways; University of Texas, Austin; Andrew Ellington, Ph.D. This project will use a novel method to evolve individual variants of cannabinoid receptor type 2 (CB2) that interact with high affinity with minor cannabinoids and evaluate the new variants in a mouse model of pain. (Grant 1R21AT010777)
  • Exploring the Mechanisms Underlying the Analgesic Effect of Cannabidiol Using Proton Magnetic Resonance Spectroscopy; University of Utah, Salt Lake City; Deborah A. Yurgelun-Todd, Ph.D. This project will use proton magnetic resonance spectroscopy (1H-MRS) to evaluate changes in brain chemistry in critical pain-processing regions after short-term administration of a cannabis extract enriched in CBD. (Grant 1R21AT010736)
  • Mechanistic Studies of Analgesic Effects of Terpene Enriched Extracts from Hops; Emory University, Atlanta; Cassandra L. Quave, Ph.D. This project will take a multidisciplinary approach to investigate the analgesic effects of terpenes from Humulus lupulus (hops), a plant that is closely related to cannabis and has a very similar terpene profile. (Grant 1R21AT010774) 
  • Systematic Investigation of Rare Cannabinoids With Pain Receptors; University of Illinois at Urbana-Champaign; David Sarlah, Ph.D. This project involves synthesizing several classes of rare phytocannabinoids, systematically evaluating their anti-inflammatory potential, and examining the effects of the compounds with the strongest anti-inflammatory potential on the major receptors involved in pain sensation. (Grant 1R21AT010761)

Analgesic efficacy of single and combined minor cannabinoids and terpenes; Temple University, Philadelphia; Sara J. Ward, Ph.D. This project will use rodent models of pain to evaluate the effects of four biologically active components of cannabis that may act synergistically to protect against pain development and to assess the interactions of these four substances with morphine. (Grant 1R01AT010778)

At NEEDED Blends, we are always researching the latest news and updates in the CBD industry as we seek to provide the highest quality and custom tailored CBD, CBG and CBN blends formulated to meet a wide variety of needs.


Needed BlendsCopyright 2020 All Rights Reserved

All Products Contain .3% THC or Less These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.